Mezzion Pharma
Seoul, South Korea · Biopharma, Biotechnology, Health Care · 9 employees
Mezzion Pharmaceuticals, Inc., a U.S.-based subsidiary of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410), is a late-stage biopharmaceutical company focused on developing therapies for rare and underserved diseases. Mezzion is advancing JURVIGO® (udenafil) through a global Phase 3 clinical program as a potential first-in-class therapy for patients with single ventricle congenital heart disease and Fonta
Funding history
- Funding Round — $20.0M — Jun 2025
- Funding Round — $40.0M — Apr 2023
Recent signals
- Jan 06, 2026: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh as President and COO
- Jun 11, 2025: Raised $20.0M
- Apr 25, 2023: Raised $40.0M
See plans & pricing → Track Mezzion Pharma ’s funding, hiring, and signals — with verified contacts — on Fundz.